Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Loos

Showing results (161-170 of 215) with videos related to

Pageof 22
Sort By:
The Oncologist|April 5, 2007
Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxelFrederike K Engels, Floris A de Jong, Alex Sparreboom, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 4, 2000
Phase I and pharmacological study of increased dose oral topotecan in combination with intravenous cisplatinA J Gelderblom, W J Loos, M J de Jonge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2002
Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicityDiederik F S Kehrer, Annelies M Bos, Jaap Verweij, et al.
Journal of the National Cancer Institute|June 15, 1994
Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09J H Schellens, A S Planting, B A van Acker, et al.
Cancer Chemotherapy and Pharmacology|July 24, 2010
Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis studyInge R H M Konings, Stefan Sleijfer, Ron H J Mathijssen, et al.
Cancer Biology & Therapy|September 18, 2007
Irinotecan chemotherapy during valproic acid treatment: pharmacokinetic interaction and hepatotoxicityFloris A de Jong, Jessica M van der Bol, Ron H J Mathijssen, et al.
Journal of Pharmaceutical and Biomedical Analysis|October 8, 2010
Simultaneous quantification of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometryWalter J Loos, Anne-Joy M de Graan, Peter de Bruijn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 20, 2009
Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I studyConstantijne H Mom, Jaap Verweij, Corina N A M Oldenhuis, et al.
International Journal of Obesity (2005)|May 21, 2008
Common SNPs in LEP and LEPR associated with birth weight and type 2 diabetes-related metabolic risk factors in twinsN Y Souren, A D Paulussen, A Steyls, et al.
Clinical Colorectal Cancer|January 17, 2015
A phase Ib study of the VEGF receptor tyrosine kinase inhibitor tivozanib and modified FOLFOX-6 in patients with advanced gastrointestinal malignanciesCorina N Oldenhuis, Walter J Loos, Brooke Esteves, et al.
Pageof 22

Showing results (161-170 of 215) with videos related to

Sort By:
Pageof 22
The Oncologist|April 5, 2007
Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxelFrederike K Engels, Floris A de Jong, Alex Sparreboom, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 4, 2000
Phase I and pharmacological study of increased dose oral topotecan in combination with intravenous cisplatinA J Gelderblom, W J Loos, M J de Jonge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2002
Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicityDiederik F S Kehrer, Annelies M Bos, Jaap Verweij, et al.
Journal of the National Cancer Institute|June 15, 1994
Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09J H Schellens, A S Planting, B A van Acker, et al.
Cancer Chemotherapy and Pharmacology|July 24, 2010
Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis studyInge R H M Konings, Stefan Sleijfer, Ron H J Mathijssen, et al.
Cancer Biology & Therapy|September 18, 2007
Irinotecan chemotherapy during valproic acid treatment: pharmacokinetic interaction and hepatotoxicityFloris A de Jong, Jessica M van der Bol, Ron H J Mathijssen, et al.
Journal of Pharmaceutical and Biomedical Analysis|October 8, 2010
Simultaneous quantification of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometryWalter J Loos, Anne-Joy M de Graan, Peter de Bruijn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 20, 2009
Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I studyConstantijne H Mom, Jaap Verweij, Corina N A M Oldenhuis, et al.
International Journal of Obesity (2005)|May 21, 2008
Common SNPs in LEP and LEPR associated with birth weight and type 2 diabetes-related metabolic risk factors in twinsN Y Souren, A D Paulussen, A Steyls, et al.
Clinical Colorectal Cancer|January 17, 2015
A phase Ib study of the VEGF receptor tyrosine kinase inhibitor tivozanib and modified FOLFOX-6 in patients with advanced gastrointestinal malignanciesCorina N Oldenhuis, Walter J Loos, Brooke Esteves, et al.
Pageof 22